Navigation Links
Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Date:4/20/2012

EAST BRUNSWICK, N.J., April 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's first quarter financial results will be released prior to the open of the market on Wednesday, May 9, 2012.
Savient executive management will host a conference call beginning at 9:00 a.m. Eastern Time on May 9, 2012, to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 72346185.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  A telephone replay will be available from 12:00 p.m. Eastern Time on May 9, 2012, through 12:00 a.m. Eastern Time on May 16, 2012, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 72346185.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT-IContact: Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
2. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
3. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
5. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
6. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
7. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
8. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
9. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
10. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... ... 2019 , ... “Comprehensive Vital Organ Biomarkers Analysis of the Consciousness Energy Healing ... No. 1 International Best Seller on Amazon in many categories including Cell Biology, Biology, ... Nosology, and Reference. , The aim of Balmer’s work was to study the ...
(Date:11/16/2019)... ... November 16, 2019 , ... International Splash Awards 2019 winners were announced and ... , Srijan got nominated for its efforts at the world-class competition acknowledging the best ... under tools and apps category. The event was organized in conjunction with DrupalCon Amsterdam ...
(Date:11/15/2019)... ... November 15, 2019 , ... Unlike fine wine, shoulder joints ... shoulder impingement syndrome and rotator cuff disease – rise after age 50, says orthopedic ... limbs. , Impingement syndrome occurs when the uppermost tendon of the rotator cuff – ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... 2019 , ... MemoryCare.com , a comprehensive resource for ... Care Facilities in Amarillo, Texas. The guide identifies 5 memory care communities based ... the Alzheimer’s Association , 5.6 million people age 65 and older are ...
(Date:11/16/2019)... , ... November 16, 2019 , ... ... support AdventHealth, one of the nation’s largest faith-based health systems, as it underwent ... massive program implementation process – from product selection to fitting events to uniform ...
(Date:11/15/2019)... ... 15, 2019 , ... DataTribe , a global cyber ... nation-state experienced technical teams from the intelligence community, research labs, and industry-leading experts, ... Inc ., based in Northport, New York. , The DataTribe Challenge ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... Care System reminds community members, businesses and organizations about the benefits of supporting ... movement that inspires hundreds of millions of people to give, collaborate and celebrate ...
(Date:11/14/2019)... ... 14, 2019 , ... EMulate Therapeutics, Inc., a clinical-stage therapeutic ... will have 5 poster presentations related to its medical devices for treating adult ... Meeting in Phoenix, beginning on November 20 . , Two posters ...
Breaking Medicine News(10 mins):